Carevec Tab. (Imatinib)

Carevec Tab. (Imatinib)
Product Description

Chronic myelogenous leukemia and acute lymphocytic leukemia

HK inno. N Corporation

  • KR
  • 2020
    On CPHI since
Specifications
  • Supplied from
    Korea, Republic of

HK inno. N Corporation

  • KR
  • 2020
    On CPHI since

More Products from HK inno. N Corporation (2)

HK inno. N Corporation resources (1)

  • News HK inno.N Corporation receives regulatory approval for first novel drug

    Korean pharmaceutical firm HK inno.N Corp. said on Friday that its gastroesophageal reflux disease drug K-CAB has been approved by the Ministry of Food and Drug Safety, marking the first time for the company to launch an independently-developed novel drug under its name. HK inno.N plans to advance into overseas markets with its first novel drug, which has already been licensed out to China’s Shandong Luoxin Pharmaceutical Group in a 100 billion won ($89.7million)